1. Home
  2. Labeler Index
  3. Aurobindo Pharma Limited
  4. 65862-245
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Levetiracetam NDC 65862-245 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

The figure shows the responder rate in Study 1 with a 250% reduction from baseline. There was a statistically significant difference between treatment and placebo groups. The percentages of responder rate range from 0% to 39.6%. The text "et Leveiacl 100 ooy Leviaseam 000 oy" is not understandable and might be a result of error.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1000 mg (500 Tablets Bottle) - levetiracetam fig10

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1000 mg (500 Tablets Bottle) - levetiracetam fig10

Each tablet of this medicine contains 1000 mg of Levetiracetam USP and it is distributed by Aurobindo Pharma USA, Inc. The tablets have a child-resistant closure and the usual dosage should be seen in the package insert. The medication guide provided should be stored separately at a temperature of 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). This medicine is made in India and its NDC code is 65862-315-05. The code TS/DRUGS9/4993 is printed on it.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

The text suggests a figure depicting the "Responder Rate" in Study 2, during "Period A", which involves a comparison of the effects of a placebo treatment versus levetiracetam treatments of different dosages in patients. The text also indicates the percentages of patients who responded to each treatment (with a 250% reduction rate from baseline), and it notes that the response rate for the 2000 mg/day dosage of levetiracetam is "statistically significant versus placebo".*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

The figure shows the responder rates (>50% reduction from baseline) in Study 3. The responder rate for placebo was 14.4% while for levetiracetam 3000 mg/day, it was 39.4% which was statistically significant compared to placebo.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

The text describes the Responder Rate in Study 4, showing a 50% reduction from baseline in two groups. The placebo group had 97 participants and the levetiracetam group had 101 participants. A statistically significant difference was observed between the two groups. The percentage of responders in the levetiracetam group was 44.6% while in the placebo group it was 19.6%.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

The figure shows the Responder Rate for patients aged 1 month to less than 4 years in Study 5, indicating a greater than 50% reduction from baseline. The data suggests that Lovetracatam had a statistically significant effect compared to placebo.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

The figure shows the Responder Rate in PGTC Seizure Frequency, with a 250% Reduction from Baseline in Study 7. It indicates that 72.2% of patients had a positive response to treatment with Levetiracetam versus 45.2% in the Placebo group. The results are statistically significant.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (500 Tablets Bottle) - levetiracetam fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (500 Tablets Bottle) - levetiracetam fig7

This is a description of Levetiracetam tablets, containing 250 mg of Levetiracetam USP. The package insert should be consulted for complete dosage recommendations. The tablets should be dispensed with a medication guide and stored in a tight, light-resistant container with child-resistant closure at room temperature. The tablets are distributed by Aurobindo Pharma USA, Inc. and manufactured in India. The code on the package is TS/DRUGS/19/1993. The packaging includes a coding area and overprinting zone.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (500 Tablets Bottle) - levetiracetam fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (500 Tablets Bottle) - levetiracetam fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (500 Tablets Bottle) - levetiracetam fig9

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (500 Tablets Bottle) - levetiracetam fig9

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.